Rethinking Fixed Processes In Cell Therapy Development
Process development rarely runs in a straight line. Expansion yields shift between stages, dose targets move, and source material varies by patient in autologous programs and by donor in allogeneic ones, sometimes mid-program. Most processing equipment runs fixed protocols, so the process bends to fit the tool.
The workarounds that follow rarely feel like big decisions: a manual step at the bench, a second device, a compromise that is close enough. Each adds run-to-run variability, and a process built on them is harder to document, transfer and defend to quality.
Often the constraint is not the hardware itself but the rigid logic governing how the machine operates. Five criteria give process development teams a way to test any processing platform, along with a look at what changes when the process is designed around the cells instead of the equipment.
Get the full article for a practical standard to hold your next platform to.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.